44 results about "Potassium oxonate" patented technology

The invention relates to a capsule preparation containing tegafur, Jimeisita and Potassium Oxonate and a preparation method thereof, which is characterized in that the capsule preparation contains tegafu micropill, Jimeisita micropill and Potassium Oxonate micropill, wherein, the micropill is prepared from active drug ingredient, thinner, bond and surface active agent. The micropill is prepared with the extruding-rolling method, the centrifugal-fluidifying method, the pan coating pill floating method and the like, and then, other minor ingredients are added; finally, the capsule is filled. The capsule prepared with the preparation method can be steadily and quickly released in bodies, thus the drug stability is improved. The capsule has high dissolution rate and biological availability, and reduces adverse reaction of medicine.

The invention belongs to the technical field of medicaments, and relates to TS-1 granules for treating advanced gastric cancer and a preparation method thereof. The method comprises the following steps of: preparing active medicaments tegafur, gimeracil and potassium oxonate into a cyclodextrin inclusion compound; and sieving the inclusion compound, uniformly mixing the sieved inclusion compound and pharmaceutically acceptable auxiliary materials and performing wet granulation or dry granulation to prepare the granules. The granules have the advantages of increasing the water solubility and stability of the medicaments, covering the bitter taste of the tegafur, prolonging the action time, improving the medication compliance of patients with cancer, greatly improving the bioavailability of the medicaments and reducing the toxic or side effect of the medicaments.

The invention refers to a capsule preparation containing tegafur, gimeracil and potassium oxonate. The capsule preparation comprises the following components by weight parts: 20 parts of tegafur, 5-6 parts of gimeracil, 19-20 parts of potassium oxonate, 10-300 parts of lactose, and 0.9-5 parts of sodium dodecyl sulfate. According to the invention, the use level of the surfactant of sodium dodecylsulfate is greatly reduced on the premise of guaranteeing rapid dissolving-out of active components in the preparation, so that the irritation of the capsule preparation to the human gastrointestinaltract is decreased and the medicine compliance of a patient is increased.

The invention relates to a method for preparing bonito stick protein hydrolysate with an effect of reducing uric acid. The method comprises the following main steps of raw material heat treatment, restriction digestion, membrane separation-anion exchange chromatography-gel filtration chromatography separation, concentration and spray drying so as to obtain the bonito stick protein hydrolysate with an effect of reducing uric acid. The amino acid analysis indicates that the zymolyte peptide fragment primary amino acid sequence contains four amino acids, namely histidine, arginine, lysine and threonine, the total mass content of the four amino acids is 70 percent of the total amino acid content of zymolyte. MALDI-TOF-MS mass spectrum determines that the molecular weight of the main peptide effective ingredient is less than 700Da. In-vitro uric acid reduction experiments prove that the bonito stick protein hydrolysate has a remarkable effect of inhibiting generation of uric acid, and has an inhibition rate over 50 percent; an oteracil potassium molded hyperuricemic rat animal model indicates that the bonito stick protein hydrolysate can be used for remarkably reducing the level of serum uric acid and serum creatinine of rats, and shows a relatively good kidney protecting effect.

The invention discloses an L.plantarum UA149 strain and an application thereof, and belongs to the field of functional food microorganisms. The L.plantarum UA149 strain is deposited in China Typical Culture Collection Center on November 29, 2018 with the preservation number of CCTCC No: M2018842. The strain can be apply to preparing products with a uric acid reducing function or a gout resisting function. Lactic acid bacteria separated and identified from the surface of fleshy plant leaves are taken as research objects, and a new strain of lactic acid bacteria is screened through a large number of experiments. Hyperuricemia model rats are established by potassium oxazinate combined with fructose water, continuous intragastric administration of the lactobacillus plantarum UA149 strain for 14 days can significantly reduce the level of uric acid; and during gout attack, the release of inflammatory factors thromboxane and leukotriene mediated by neutrophils is reduced, the influx of neutrophils into joints is avoided, and the symptoms of redness, swelling, pain, heat and the like are reduced.

The invention discloses a method for building an animal model with hyperuricemia-combined diabetes. The method comprises the following steps: 1) feeding an target animal with fodder containing 10% (by mass) of yeast powder; subjecting the target animal to a lavage with a 4% (by mass) adenine water solution according to the following dosage of 100 milligram of adenine per day per kilogram of body weight until the blood uric acid level of the target animal starts falling; 2) halving the dosage of the adenine water solution in step 1), subjecting the target animal to a subcutaneous injection with an oteracil potassium emulsion twice a day according to the following dosage of 100 milligram of oteracil potassium emulsion per day per kilogram of body weight until the target animal shows clinical symptoms of diabetes, and then obtaining the animal model with the hyperuricemia-combined diabetes. The method builds the animal model with the hyperuricemia-combined diabetes for the first time, the animal model has typical disease symptoms, the quantity index has statistical significance, and studies such as glucose clamp test and immunohistochemistry also prove that the modeling is successful. Therefore, the method for building the animal model with the hyperuricemia-combined diabetes is a reliable and practical technique.

The invention provides a method for refining high-purity potassium oxonate. The method is characterized by comprising the following steps: adding an potassium oxonate crude product into water; adding alkali into the water until the crude product is completely dissolved; adding a polar solvent into the solution; adjusting the pH of the solution to neutrality by acid; filtering and separating out crystal; and drying the crystal so as to obtain the high-purity potassium oxonate. The method has the advantages of simple operation, mild reaction condition, high yield, pure product and the like, and has yield over 90 percent, purity over 99.95 percent (detected by HPLC), and a single impurity peak reduced from 0.5 percent to below 0.05 percent.

The invention provides a synthesis technology for preparing oteracil potassium. With short reaction steps, the technology avoids the adoption of toxic and harmful bromine as an oxidant. The synthesis technology is characterized by comprising the following step of dissolving allantoin in a potassium hydroxide or potassium carbonate aqueous solution, wherein potassium iodide is used as a catalyst, and a pypocholoride aqueous solution is used as an oxidant. The method provided by the invention has the advantages of simplicity in operation, mild reaction conditions, high yield, high product purity and the like, and is suitable for industrial production of oteracil potassium.

The invention discloses a micro-pill containing tegafur, gimeracil and potassium oxonate, a capsule preparation and a preparation method for the micro-pill. The micro-pill comprises a tegafur drug layer-coated pill core, an isolation layer and a coating layer containing gimeracil and potassium oxonate. Tegafur, gimeracil and potassium oxonate are ground by airflow, the micro-pill is directly coated with a drug through an empty pill core, additional auxiliary materials are prepared into granules by a fluidized bed, the micro-pill is uniformly mixed with the additional auxiliary material granules, and a capsule is directly filled with a mixture. The prepared capsule is capable of enabling the drug to be stably and quickly released in bodies, remarkably improves the content uniformity and stability of the drug, has relatively high dissolution rate and bioavailability, reduces adverse drug reactions and can be commercially produced.

The invention provides a preparation method of a tegafur gimeracil oteracil potassium capsule. The preparation method comprises the following steps of: dispersing tegafur, gimeracil and potassium oxonate in a hydrophilic material aqueous solution; grinding by utilizing a ball mill; then spray-drying; evenly mixing the spray-dried material with a lubricant; and filling the mixture into a capsule.

The invention belongs to the technical field of chemical synthesis and particularly relates to a method for preparing potassium oxonate, comprising the following steps: dissolving potassium hydroxide in water, clarifying and then cooling to 0-5 DEG C, adding potassium iodide, adding allantoin in batch, stirring for dissolving, dropwise adding bromine at a controlled temperature of 0-5 DEG C for 7-11 h, stirring at 0-5 DEG C for 1 after dropwise adding, heating to 20-25 DEG C and reacting for 18-22 h, and detecting allantoin being <0.6% through HPLC (high performance liquid chromatography), cooling to 0-5 DEG C, dropwise adding acetic acid to adjust pH to 5, filtering, washing with water, washing with ethanol, and drying to obtain the potassium oxonate. The method has good reaction effect, high product yield and low cost, is simple to perform and is particularly applicable to industrial application.

The invention discloses a water treatment material for heavy metal wastewater. The water treatment material is prepared from, by weight, 10-13 parts of psilotum nudum, 6-11 parts of horsetail, 7-10 parts of water chestnut root, 20-30 parts of phenolic resin, 12-15 parts of propylene glycol, 8-12 parts of salicylol, 7-12 parts of cellulose ether, 3-6 parts of 2-amino-5-nitrothiazole, 6-10 parts of 2-hydroxy ethyl acrylate, 2-6 parts of ammonium acetate, 3-7 parts of potassium oxonate and 4-8 parts of 3'-hydroxyacetophenone. The water treatment material is mainly prepared from phenolic resin modified by plants such as psilotum nudum, horsetail and water chestnut root. The treatment material is good in effect of adsorbing heavy metal ions and good in reuse effect after being regenerated simply.

Compositions comprising potassium taurate bicarbonate complexes and / or potassium taurate ascorbate complexes are useful as pharmaceutical compositions and as dietary ingredients in nutritional supplements, medical foods, and other foods. In preferred embodiments, potassium taurate bicarbonate and / or potassium taurate ascorbate complexes are the active ingredient in antihypertensive drug products that are intended to lower or prevent elevated blood pressure, or as dietary ingredients in dietary supplements, medical foods or other foods that are intended to supply a source of potassium, taurine, ascorbate, and / or bicarbonate, or that are intended to help maintain normal blood pressure levels and / or normal muscle mass. In preferred embodiments, potassium taurate bicarbonate complexes are prepared by intermixing potassium bicarbonate and taurine in aqueous solutions, and potassium taurate ascorbate complexes are prepared by intermixing potassium ascorbate and taurine in aqueous solutions.

The invention provides a method for refining high-purity potassium oxonate. The method is characterized by comprising the following steps: adding an potassium oxonate crude product into water; adding alkali into the water until the crude product is completely dissolved; adding a polar solvent into the solution; adjusting the pH of the solution to neutrality by acid; filtering and separating out crystal; and drying the crystal so as to obtain the high-purity potassium oxonate. The method has the advantages of simple operation, mild reaction condition, high yield, pure product and the like, andhas yield over 90 percent, purity over 99.95 percent (detected by HPLC), and a single impurity peak reduced from 0.5 percent to below 0.05 percent.

The invention discloses a compound shown as a formula I, and also discloses a preparation method of the compound and application of the compound as an impurity reference substance in check of potassium oxonate related substances. Due to the implementation of the compound, the quality of the potassium oxonate is effectively controlled, thus having significance to safe medication of the masses.

A strain of Lactobacillus plantarum UA149 and its application belong to the field of functional food microorganisms. A strain of Lactobacillus plantarum (L. plantarum) UA149 of the present invention has been preserved in the China Center for Type Culture Collection on November 29, 2018, with the preservation number CCTCC NO: M2018842. The bacterial strain can be used in the preparation of products with uric acid-lowering function or anti-gout function. The invention takes the lactic acid bacteria isolated and identified from the surface of succulent leaves as the research object, and a new strain of the lactic acid bacteria is screened out through a large number of experiments. Hyperuricemia model rats were established by using potassium oxonate combined with fructose water, and intragastric administration of Lactobacillus plantarum UA149 strain for 14 days could significantly reduce blood uric acid levels; during gout attacks, neutrophil-mediated inflammation could be reduced. The release of sex factor thromboxane and leukotrienes prevents the influx of neutrophils into the joints and reduces redness, pain, heat and other symptoms.

The invention discloses an anti-gout active polypeptide RDP2 as well as a preparation method and application thereof. An amino acid sequence of the anti-gout active polypeptide RDP2 is AAAAGAMPK-NH2.The anti-gout active polypeptide RDP2 obtained by purification displays higher uric acid reducing activity in an oteracil potassium induced hyperuricemia animal model experiment and shows better relieving capacity in a monosodium urate crystal induced gout attack animal model, revealing that the anti-gout active polypeptide RDP2 has potential application prospects. The anti-gout active polypeptideRDP2 has the beneficial characteristics of simple structure and high anti-gout activity.

The invention relates to an oral disintegrating preparation containing tegafur, gimeracil and oteracil potassium. The oral disintegrating preparation also includes carbohydrates and a disintegrating agent. Active ingredients in the oral disintegrating preparation are high in dissolution rate so that a drug is ensured to work quickly. More importantly, the oral disintegrating preparation is good in stability, is free of surfactants, is reduced in irritation to human gastrointestinal tract and improves patient compliance. The oral disintegrating preparation is simple in preparation technology and is suitable for industrial production.

The invention relates to application of hirudin as a medicine for preventing and treating hyperuricemia, and discloses novel application of the hirudin for preparing a medicine for preventing and treating the hyperuricemia and diseases caused by the hyperuricemia; Kunming mice are induced by hypoxanthine and potassium oxonate to establish hyperuricemia models, and intervention effects of the hirudin on the hyperuricemia are observed. Research results show that the use of the hirudin for 12 consecutive days in the Kunming mice significantly reduces a serum uric acid level in hypoxanthine-induced hyperuricemia mice; the hirudin can also be used to prepare medicines for the hyperuricemia and the diseases caused by the hyperuricemia: obstructive sleep apnea and / or menopause syndrome, or hypertension, hyperlipidemia, atherosclerosis, obesity, insulin resistance, nephropathy, inflammation, infectious diseases, tumor lysis syndrome and other diseases. New application of the hirudin is openedup.

The invention relates to a traditional Chinese medicine composition for gout. The traditional Chinese medicine composition is prepared from 10-35 parts of rhizoma alismatis, 5-20 parts of semen plantaginis, 5-20 parts of radix angelicae, 5-20 parts of rhizoma paridis, 2-10 parts of herba ephedrae, 0.01-1 part of menthol, 0.05-4 parts of borneol and 1-10 parts of liquorice root. The traditional Chinese medicine composition has a good uric acid reducing effect on a zebra fish hyperuricemia model caused by oteracil potassium combined with xanthine.

The invention relates to a preparation method of a capsule containing tegafur, gimeracil and potassium oxonate. The preparation method is characterized in that gimeracil is added in a form of micronized solid. The preparation method related by the invention overcomes bad water solubility of gimeracil by utilizing a micronized technology, thus the improvement of medicament dissolution is facilitated.

The present invention relates to a method for constructing a mouse model of acute hyperuricemia, which comprises the following steps: giving the test mice a diet containing hairtail fish every day to carry out a modeling test for 7 to 8 days; at the end of the modeling test For two days, hypoxanthine and potassium oxonate were administered each day. Its beneficial effect is that the construction method of the mouse model of acute hyperuricemia of the present invention, due to the combination of hypoxanthine, potassium oxonate and hairtail as a modeling agent, compared with the prior art, it can be achieved by The synergistic effect of multiple mechanism modeling agents prepares a model similar to the pathogenesis of human hyperuricemia, thereby reducing the time for modeling.

The invention provides an application of baishouwu benzophenone in preparation of a uric acid reducing medicine, and belongs to the technical field of medicines. A test result shows that the baishouwu benzophenone can obviously reduce the blood uric acid level of mice with hyperuricemia induced by oteracil potassium, the titer of the baishouwu benzophenone is higher than that of a 1mg / kg dosage group of a positive drug febuxostat, and the difference has significant statistical significance; and meanwhile, the blood uric acid level of the mice with uric acid induced hyperuricemia can be remarkably reduced by using 8.0 mg / kg and 16.0 mg / kg dosage groups of the baishouwu benzophenone, certain dose dependence exists, compared with the positive drug, the titer of the baishouwu benzophenone is higher than that of a 25mg / kg dosage group of the positive drug benzbromarone, and the difference has significant statistical significance. The baishouwu benzophenone provided by the invention achieves a good uric acid reducing effect in the application of preparing the uric acid reducing medicine, and is safe and free of sequelae.

The invention belongs to the technical field of drugs, in particular to a pure traditional Chinese medicine anti-gout dropping pill; the invention develops a new generation strong-efficient non-toxic drug for treating gout-the pure traditional Chinese medicine anti-gout dropping pill which is characterized by correcting complicating disease of gout rapidly by taking the search of characteristic compounds or natural effective mixed compounds for inhibiting the formation of uric acid, enhancing the dissolution and the precipitation of urate which is deposited in joints, soft tissues, soft bonesand kidney, promoting the discharge of the uric acid from renal tubule and recovering the self-excretion ability of the uric acid of the kidney as the base point. The pure traditional Chinese medicine anti-gout dropping pill is formed by mixing volatile oil of argyi wormwood leaf, total terpenes of the argyi wormwood leaf and total glucosides of plantain seed according to certain proportion and aplurality of experiments, the pure traditional Chinese medicine anti-gout dropping pill can effectively reduce the uric acid level in blood of mice with potassium oxonate-induced hyperuricemia and greatly improve and effectively cure the potassium oxonate-induced joint swelling and mobility difficulty, and the development and the use of the new drug can allow the drug to become the specific anti-gout new drug.

The invention provides the application of Radix Polygonum benzophenone in the preparation of uric acid-lowering medicine, which belongs to the technical field of medicine. The test results showed that Baishouwu benzophenone could significantly reduce the blood uric acid level in mice with hyperuricemia induced by potassium p-oxonate, and its potency was stronger than that of the positive drug febuxostat 1mg / kg dose group, the difference was significant. Statistically significant; at the same time, the 8.0mg / kg and 16.0mg / kg dose groups of Radix Polygonum benzophenone can significantly reduce the blood uric acid level of mice with uric acid-induced hyperuricemia, and there is a certain dose-dependence, Compared with the positive drug, its potency is stronger than that of the positive drug benzbromarone 25mg / kg dose group, and the difference is statistically significant. The application of the Radix Polygoni Multiflori benzophenone provided in the present invention in the preparation of uric acid-lowering medicines has achieved good uric acid-lowering effects and is safe and has no sequelae.

The invention relates to an oral solid enteric extended-release tegafur-gimeracil-potassium oxonate medicinal preparation (a tablet or capsule) and a preparation method thereof, belonging to the technical field of extended-release preparations of drugs. The release form of drugs may be extended release, quick release or double release (extended release and quick release); the release effect enables plasma concentration to be stationary and avoids the phenomenon of peak-valley fluctuation of plasma concentration; and thus, the bioavailability and curative effect of drugs are improved, and administration frequency and total dose are reduced, which enables toxic and side effect on gastrointestinal tracts and the like to be reduced and medication compliance to be improved. The oral solid enteric extended-release tegafur-gimeracil-potassium oxonate medicinal preparation is applicable to treatment of locally advanced or metastatic (i.e., cases where tumor tissue cannot be surgically removed)gastric cancer, head and neck cancer, colorectal cancer, non-small cell lung cancer, breast cancer, pancreatic cancer, bile duct cancer, cervical cancer, prostate cancer, etc.

The invention discloses a compound shown as a formula I, and also discloses a preparation method of the compound and application of the compound as an impurity reference substance in check of potassium oxonate related substances. Due to the implementation of the compound, the quality of the potassium oxonate is effectively controlled, thus having significance to safe medication of the masses.

The invention relates to a construction method of an acute hyperuricemia mouse model. The method comprises the following steps: feeding a test mouse with a hairtail-containing feed every day, performing a 7-8-day modeling test; and in the last two days of the modeling test, respectively feeding the mouse with hypoxanthine and oteracil potassium every day. The method has the beneficial effects that: according to the construction method of the acute hyperuricemia mouse model, due to the fact that hypoxanthine, oteracil potassium and hairtail are adopted as the combination of a modeling agent, compared with the prior art, the model similar to the human body hyperuricemia attack process can be prepared through the synergistic effect of multiple machine modeling agents, and therefore the modeling time is shortened.

The invention provides the application of 3-acetylaminocoumarin in the preparation of medicine for treating or preventing hyperuricemia, and also provides the application of 3-acetamidocoumarin in the preparation of medicine for treating or preventing kidney damage. The present invention induces hyperuricemia in mice by potassium oxonate and hypoxanthine, and 5-100 mg / kg / d of 3-acetamidocoumarin is orally administered, wherein the blood uric acid level of the mice in the model group is significantly increased, and the kidney The damage was significant; the blood uric acid level of mice in the administration group decreased significantly, and the kidney protection effect was remarkable.